MetaCap

Kyverna Therapeutics (KYTX) vs Lexeo Therapeutics (LXEO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kyverna Therapeutics (KYTX) has outperformed Lexeo Therapeutics (LXEO) over the past year, losing 39.9% versus a loss of 67.3%. Kyverna Therapeutics is the larger company by market cap ($269.3 million vs $245.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KYTX-39.92%LXEO-67.33%
+65%-6%-77%
Nov 21, 20251 yearNov 20, 2026
KYTX-85.85%LXEO-82.10%
+11%-44%-99%
Feb 5, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KYTX versus LXEO key metrics
MetricKYTXLXEO
Share price$4.26$2.96
Market cap$269.33M$245.05M
1-day change-2.52%+0.34%
YTD return-54.68%-70.19%
1-year return-39.92%-67.33%
EPS (TTM)$-2.75$-1.13
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-161.31M$-100.00M
52-week high$13.67$10.99
52-week low$4.18$2.55
Distance from 52-week high-68.84%-73.07%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+613.62%+748.31%
Average volume867.28K1.98M
Shares outstanding63.22M82.79M
Employees17268
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KYTX has outperformed LXEO by 27.4 percentage points over the past year.

About Kyverna Therapeutics

KYTX stock →

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 172 employees

About Lexeo Therapeutics

LXEO stock →

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 68 employees

KYTX vs LXEO FAQ

Which is bigger, Kyverna Therapeutics or Lexeo Therapeutics?

Kyverna Therapeutics (KYTX) is larger, with a market capitalization of $269.33M compared with $245.05M for Lexeo Therapeutics (LXEO).

Which stock has performed better over the past year, KYTX or LXEO?

KYTX returned -39.92% over the past 12 months, compared with -67.33% for LXEO (price return, excluding dividends). Past performance does not predict future results.

Are Kyverna Therapeutics and Lexeo Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons